FDA Approves First Self-Administered FluMist Nasal Spray for At-Home Use

Sep 20, 2024, 08:03 PM

The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self- or caregiver-administration. This approval marks the first time a flu vaccine can be administered at home without the need for a healthcare provider. FluMist is licensed for individuals between the ages of 2 and 49 and is designed to prevent influenza caused by virus subtypes A and B. The vaccine, which contains a weakened live virus, will be available through third-party pharmacies, where individuals will complete a screening and eligibility assessment when ordering. This move is part of a broader effort by the FDA to expand consumer access to medicines and reduce costs and barriers to care.